Geron Highlights RYTELO Launch, 2026 Revenue Outlook and Phase 3 Myelofibrosis Plans at Needham Conf

Geron (NASDAQ: GERN) executives used a presentation at the Needham Healthcare Conference to outline the company's early commercial trajectory for its telomerase inhibitor imetelstat (marketed as RYTELO) in lower-risk myelodysplastic syndromes (MDS), provide updated views on physician adoption dynamics, and discuss the ongoing Phase 3 myelofibrosis (MF) program. Commercial launch status and financial outlook President and